CureMatch, a San Diego, CA-based digital health company focusing on personalized medicine and combination therapy in oncology, closed a bridge round to Series A financing.
The bridge round – whose amount was not disclosed – was oversubscribed, with Serra Ventures and tech entrepreneur Phil Trubey as major investors.
The company is using the funds to expand sales and marketing efforts.
Led by Blaise Barrelet, CEO, CureMatch offers a data-driven report that scores combinations of cancer drugs that are tailored for individual patients. The report is generated using a decision support system, which can analyze millions of cancer treatment options with proprietary algorithms and evidence-based, custom-curated databases of genomics and proteomics information.
The company is now starting discussions with Series A investors.